A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Completed · Phase 3 · NCT04901195
Conditions: Hidradenitis Suppurativa
At a glance
- Research payments reported, 2025
- $738,404
- U.S. investigators named
- 27
- Sites paid
- 30
- Planned or actual enrollment
- 658
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Bimekizumab (drug)
- Dates
- Started 2021-05-27; completion 2026-07-22
- Results posted
- Not yet
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $738,404 in research payments for this study in 2025 (32 payments).
Products named: Bimzelx
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Boni Elewski Dermatology · Birmingham, AL
- Lindsay S. Ackerman, MD Dermatology · Phoenix, AZ
- Navid Ezra, M.D. Dermatology · Thousand Oaks, CA
- Vivian Laquer, M.D. Dermatology · Irvine, CA
- Walter K. Nahm, M.D., PHD. Dermatology · San Diego, CA
- Hadar A. Lev-tov, MD Dermatology · Miami, FL
- Tory Sullivan, M.D. Dermatology · North Miami Beach, FL
- Carlos G. Wambier, MD, PHD Dermatology · Miami, FL
- Scott T. Guenthner, MD Dermatology · Greenwood, IN
- Hollis J. Clark, MD Internal Medicine · Murray, KY
- Alexandra B. Kimball, MD MPH Dermatology · Boston, MA
- Robert Nossa, MD Dermatology · Marstons Mills, MA
- Wendy L. Mcfalda, D.O. Dermatology · Clarkston, MI
- Rita O. Pichardo, MD Dermatopathology · Winston Salem, NC
- Christopher J. Sayed, MD Dermatology · Chapel Hill, NC
- Joel Schlessinger, M.D Dermatology · Omaha, NE
- Jerry Bagel, MD Dermatology · East Windsor, NJ
- John R. Durkin, MD Dermatology · Albuquerque, NM
- Alice B. Gottlieb, M.D. Dermatology · Somers, NY
- Nadine Kaskas, M.D. Dermatology · New York, NY
- Alan B. Fleischer JR., MD Dermatology · Cincinnati, OH
- Jessica A. Kaffenberger, M.D. Dermatology · Columbus, OH
- Jeffrey B. Travers, MD, PH.D. Dermatology · Dayton, OH
- Kathleen P. Gordon, DO Internal Medicine · Johnston, RI
- Lara Wine Lee, M.D. Dermatology · Charleston, SC
- Michael H. Gold, M.D. Specialist · Nashville, TN
- Angela Y. Moore, MD, PA Dermatopathology · Arlington, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Beth Israel Deaconess Medical Center, MA $78,150
- Clinical PArtners LLC $69,915
- University of North Carolina at Chapel Hill $68,786
- US Dermatology PArtners Phoenix 7th St $63,375
- Icahn Institute/genetics $63,247
- University of Alabama Hospital, AL $55,455
- The Indiana Clinical Trials Center PC $48,698
- Tennessee Clinical Research Center $43,210
- Advanced Medical Research $40,504
- Altoona Center for Clinical Research $32,021
- Michigan Center for Research Company $23,034
- Essential Medical Research LLC $22,736
- University of Cincinnati $18,476
- The Ohio State University $15,600
- Clinical Trials Research Institute $14,913
- Wake Forest University Health Sciences $14,200
- Arlington Research Center Inc $13,836
- First Oc Dermatology Research Inc $13,450
- Sullivan Dermatology $7,807
- Skin Specialists P C $7,711
- Rhode Island Hospital, RI $7,232
- University of New Mexico $6,770
- University of Miami $2,250
- University Clinical Trials Inc $2,078
- Medical Univ. of S. Carolina $1,690
- Schweiger Dermatology P C $1,500
- The Psoriasis Treatment Center of Central New Jersey $880
- Icahn School of Medicine at Mount Sinai $811
- Wright State Physicians, Inc $70
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.